Id Counterfeit Pharmaceuticals with Portable Raman
Rigaku
Hot Topics > Lifecycle management
Lifecycle management
As R&D productivity declines and the age of blockbuster medicines reaches an end, the pharmaceutical industry is looking at ways to extend the profitable life of its products up to and beyond patent expiry.
Mylan partners to create FOBs
30-Jun-2009 - Mylan has followed Teva’s lead by partnering to develop follow-on biologics (FOB), with the Indian generic maker regarding Biocon as the “ideal partner” to help it enter the market. ...
Bio drugs to dominate top ten list by 2014
18-Jun-2009 - Seven of the top ten drugs will be biopharmaceuticals by 2014 according to sector analysts Evaluate Pharma.
Mega deals not ‘mega’ for Big Pharma R&D long term, says F&S
17-Jun-2009 - As rumours of a failed Sanofi Aventis’ bid for a US rival circulate, F&S’ analysis of M&As is well timed, even if its conclusions will be difficult reading for a...
FTC calls for biogenerics path and end of “pay for delay” deals
11-Jun-2009 - The US Federal Trade Commission (FTC) believes that an effective FOB approval pathway and laws preventing “pay-for-delay” deals are the only ways of reducing the cost of biologic drugs.
FDA revises ICH Q8 guidance
10-Jun-2009 - The FDA has revised its guidance on ICH Q8, adding an annex that clarifies the original document and adds the principles of quality by design (QbD).
UK trade office may check GSK and Pfizer HIV joint-venture
28-May-2009 - GSK and Pfizer’s HIV joint venture (JV) may be subject to an investigation by UK competition watchdog the Office of Fair Trading (OFT), according to various media reports.
BIO 2009: snapshot of an evolving biotech industry
22-May-2009 - in-Pharmatechnologist's Nick Taylor looks back on BIO 2009, an event at which uncertainty about the development of the biotechnology industry’s future shape dominated proceedings.
Healthcare reform could suffocate innovation; BIO 2009
22-May-2009 - Karl Rove and Senator Tom Daschle were among the political figures at BIO 2009 discussing how the US healthcare system should be reformed, which some believe could have grave consequences...
Biosimilar bill could be "stake in the heart"
19-May-2009 - In a session chaired by at BIO 2009 John Lechleiter, CEO at Eli Lilly, speakers discussed patent reform, biosimilar bills and why certain options on the table could be a...
Mutiple parameters are key to powder analysis, says Freeman
18-May-2009 - Freeman Technologies, which showcased its FT4 Rheometer at Achema in Frankfurt, Germany, last week, says pharmaceutical powders are complex systems that require analysis of multiple parameters.
Hospira calls time on US biogenerics delays
06-May-2009 - Drug delivery specialist Hospira has set up a “biologics clock” that counts the amount spent on cell culture-derived medications in the US in a bid to highlight the potential savings...
Sanofi seeks collaborators for €200m biotech plant
05-May-2009 - French drug major Sanofi Aventis has unveiled plans for a €200m ($268m) biotechnology investment at its manufacturing facility in Vitry-sur-Seine near Paris, under its collaborative Biolaunch project.
Pfizer eyes FOBs and small to midsized deals
30-Apr-2009 - Pfizer is monitoring opportunities in follow-on biologics and continuing to look for small to mid-sized deals as it plans for life without Lipitor, global revenues of which fell by 13...
Lilly & Amylin team up to create diabetes pen
30-Apr-2009 - Eli Lilly and Amylin Pharmaceuticals are jointly developing an exenatide once weekly pen device, which should provide a more convenient way for diabetics to treat themselves.
Sanofi pulls plug on four Ph III drugs
29-Apr-2009 - Sanofi-Aventis has halted development of four Phase III drugs in a “rigorous” pre-patent loss pipeline review that has also seen it drop four Phase II candidates and six Phase I...
Nanoparticles used to create topical Viagra rival
29-Apr-2009 - Erectile dysfunction could be treated by a nanoparticle formulation applied directly to the penis, according to research, reducing the side effects that can occur when taking drugs like Viagra.
Hovione shows off Irish API plant
23-Apr-2009 - API maker Hovione’s manufacturing facility in Cork, Ireland was unveiled at an opening ceremony yesterday just two weeks after the previous owner, global drug giant Pfizer, formally handed over the...
Pfizer moves for Indian unit, following Novartis’ lead
15-Apr-2009 - Pfizer is the latest company to seek greater control of its Indian subsidiary, falling into step with Swiss drug major Novartis which made a similar move late last month. ...
Shire to close Owings Mills Adderall XR plant
08-Apr-2009 - Biopharmaceuticals firm Shire will cease manufacture at its plant in Owings Mills, Maryland, US with the loss of 260 jobs in the latest stage of its plan to wind up...
Intelligent sorbents can save “6-12 months of development”
06-Apr-2009 - The use of intelligent sorbents to improve product stability can save companies six to 12 months of development and boost revenues, according to Adrian Possumato, global director at Multisorb.
Altea inks deal to use Byetta with PassPort patch
02-Apr-2009 - The search for more convenient diabetes treatments continues, with Altea Therapeutics reaching a $46m agreement with Eli Lilly and Amylin to develop a transdermal patch administering Byetta.
Flexibility is key for processing sector says Millipore
26-Mar-2009 - Flexibility is going to be a key driver for the pharmaceutical market in the next few years, according to Millipore's VP of downstream processing Paul Chapman.
GSK may move for Botox maker Allergan
25-Mar-2009 - The pharmaceutical rumour mill is still spinning with the latest speculation that UK drug major GSK is interested in Botox manufacturer Allergan causing the US firm’s share price to leap...
Pharma mega mergers a boon for Patheon's restructuring service, says CEO
25-Mar-2009 - The global economic downturn, impending blockbuster patent expiries and the wave of consolidation sweeping the pharmaceutical industry will drive demand for Patheon’s restructuring service according to CEO Wesley Wheeler. ...
Skin care firm Stiefel considers $4bn sale
23-Mar-2009 - Dermatology drug specialist Stiefel Laboratories may be looking for a Big Pharma buyer according to various media reports.
Most Popular News
Key Industry Events
Products
On demand Supplier Webinars
Discover innovative single-use mixer for efficient mixing of low shear and particulate sensitive solutions in cGMP environment
ATMI Life Science
ATMI Life Science
